Abstract
The heat shock protein (Hsp) family is an evolutionarily conserved system that is charged with preventing unfolded or misfolded proteins in the cell from aggregating. In Alzheimers disease, extracellular accumulation of the amyloid β peptide (Aβ) and intracellular aggregation of the microtubule associated protein tau may result from mechanisms involving chaperone proteins like the Hsps. Due to the ability of Hsps to regulate aberrantly accumulating proteins like Aβ and tau, therapeutic strategies are emerging that target this family of chaperones to modulate their pathobiology. This article focuses on the use of Hsp-based therapeutics for treating primary and secondary tauopathies like Alzheimers disease. It will particularly focus on the pharmacological targeting of the Hsp70/90 system and the value of manipulating Hsp27 for treating Alzheimers disease.
Keywords: Heat shock proteins, chaperones, neurodegeneration, alzheimer, Hsp27, Tau, heat shock proteins (Hsps), 42-amino acid version, Alzheimer's disease
Current Neuropharmacology
Title: Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics
Volume: 9 Issue: 4
Author(s): Jose F. Abisambra, Umesh K. Jinwal, Jeffrey R. Jones, Laura J. Blair, John Koren III and Chad A. Dickey
Affiliation:
Keywords: Heat shock proteins, chaperones, neurodegeneration, alzheimer, Hsp27, Tau, heat shock proteins (Hsps), 42-amino acid version, Alzheimer's disease
Abstract: The heat shock protein (Hsp) family is an evolutionarily conserved system that is charged with preventing unfolded or misfolded proteins in the cell from aggregating. In Alzheimers disease, extracellular accumulation of the amyloid β peptide (Aβ) and intracellular aggregation of the microtubule associated protein tau may result from mechanisms involving chaperone proteins like the Hsps. Due to the ability of Hsps to regulate aberrantly accumulating proteins like Aβ and tau, therapeutic strategies are emerging that target this family of chaperones to modulate their pathobiology. This article focuses on the use of Hsp-based therapeutics for treating primary and secondary tauopathies like Alzheimers disease. It will particularly focus on the pharmacological targeting of the Hsp70/90 system and the value of manipulating Hsp27 for treating Alzheimers disease.
Export Options
About this article
Cite this article as:
F. Abisambra Jose, K. Jinwal Umesh, R. Jones Jeffrey, J. Blair Laura, Koren III John and A. Dickey Chad, Exploiting the Diversity of the Heat-Shock Protein Family for Primary and Secondary Tauopathy Therapeutics, Current Neuropharmacology 2011; 9 (4) . https://dx.doi.org/10.2174/157015911798376226
DOI https://dx.doi.org/10.2174/157015911798376226 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Chemoprotective Mechanism of the Natural Compounds, Epigallocatechin- 3-O-Gallate, Quercetin and Curcumin Against Cancer and Cardiovascular Diseases
Current Medicinal Chemistry Fullerenes: From Carbon to Nanomedicine
Mini-Reviews in Medicinal Chemistry Protective Effect of Zinc on Mouse Renal Ischemia-reperfusion Injury by Anti-apoptosis and Antioxidation
Current Pharmaceutical Biotechnology Heat Shock Proteins - Two Sides of a Coin
Current Cardiology Reviews Phosphodiesterase 5 Inhibitors in the Treatment of Erectile Dysfunction
Current Pharmaceutical Design Identifying S100B as a Biomarker and a Therapeutic Target For Brain Injury and Multiple Diseases
Current Medicinal Chemistry The Economic Costs for the Control of Cardiovascular Risk: An Overview
Current Pharmaceutical Design Integrin Signaling Networks in the Pathobiology of Vascular Smooth Muscle Cells
Vascular Disease Prevention (Discontinued) Hematoma Expansion: Clinical and Molecular Predictors and Corresponding Pharmacological Treatment
Current Drug Targets Prevention of Contrast Induced Nephropathy
Current Drug Therapy Nanotherapeutics in Neuropathologies: Obstacles, Challenges and Recent Advancements in CNS Targeted Drug Delivery Systems
Current Neuropharmacology Peroxisome Proliferator-Activated Receptors: The Nutritionally Controlled Molecular Networks that Integrate Inflammation, Immunity and Metabolism
Current Nutrition & Food Science Design, Synthesis, and Biological Evaluation of Novel Tetramethylpyrazine- nitrone Derivatives as Antioxidants
Letters in Drug Design & Discovery Pro-angiogenic Molecules for Therapeutic Angiogenesis
Current Medicinal Chemistry Does Caffeine Affect Cardiovascular Responses?
Vascular Disease Prevention (Discontinued) Endocannabinoids in Liver Disease and Hepatic Encephalopathy
Current Pharmaceutical Design Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders
Endocrine, Metabolic & Immune Disorders - Drug Targets Poly(ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors in Cancer Chemotherapy
Recent Patents on Anti-Cancer Drug Discovery Estrogen Regulation of MicroRNA Expression
Current Genomics Inhibition of Cytochrome P450 1A2-Mediated Metabolism and Production of Reactive Oxygen Species by Heme Oxygenase-1 in Rat Liver Microsomes
Drug Metabolism Letters